Subscribe for unlimited access to DynaMed content, CME/CE & MOC credit, and email alerts on content you follow.

Already subscribed? Sign in now

Learn more about CME

Antiplatelet and Anticoagulant Drugs for Elective Percutaneous Coronary Intervention (PCI)

MoreVert
AddCircleOutlineFollow
ShareShare
AddCircleOutlineFollow
Follow
ShareShare
Share
8 Oct 2019

in patients who received ticagrelor plus aspirin therapy for 3 months after PCI and had no major bleeding or ischemic event, switching to ticagrelor monotherapy may decrease risk of bleeding without increasing risk of composite of all-cause death, nonfatal myocardial infarction, and nonfatal stroke up to 1 year compared to continuation of ticagrelor plus aspirin (N Engl J Med 2019 Sep 26 early online)

3 Oct 2019

edoxaban-based regimens may reduce bleeding risk after 14 days and may have similar risk of ischemic events up to 1 year compared to vitamin K antagonist-based regimens in adults with atrial fibrillation having percutaneous coronary intervention for stable coronary artery disease or acute coronary syndrome (Lancet 2019 Sep 2 early online)

16 Sep 2019

addition of ticagrelor to aspirin may reduce risk of myocardial infarction and stroke but increases risk of major bleeding in patients with type 2 diabetes and stable coronary disease and history of PCI (Lancet 2019 Aug 30 early online)

12 Jul 2019

in patients having PCI with drug-eluting stents, DAPT for > 12 months increases risk of bleeding and noncardiac death compared to DAPT for ≤ 6 months, but risk of all-cause death, cardiac death, and stroke remains similar regardless of DAPT duration (BMJ 2019 Jun 28)

2 Jul 2019

P2Y12 inhibitor monotherapy after 3 months of DAPT may have similar risk of major adverse cardiac and cerebrovascular events compared to continuation of DAPT for 1 year in patients having PCI (JAMA 2019 Jun 25)

2 Jul 2019

1-month DAPT regimen followed by clopidogrel monotherapy appears to reduce 1-year risk of bleeding compared to 1-year DAPT regimen after PCI, but may not reduce risk of cardiovascular adverse events (JAMA 2019 Jun 25)

25 Mar 2019

intravenous monoclonal antibody PB2452 reported to rapidly reverse antiplatelet effects of ticagrelor in randomized phase I trial in 64 healthy volunteers (N Engl J Med 2019 Mar)

23 Oct 2018

DAPT for 6 months or 12 months may have similar composite risk of all-cause death, major adverse cardiac and cerebrovascular events, and major bleeding in patients who are event free for 6 months following primary PCI for STEMI (BMJ 2018 Oct 2)

7 Oct 2018

recent (≤ 3 months previously) discontinuation of thienopyridine associated with increased risk of myocardial infarction in patients who had dual antiplatelet therapy for 12 or 30 months after percutaneous coronary intervention with stent placement (Circulation 2017 May 2)

7 Oct 2018

ticagrelor 60 or 90 mg twice daily associated with greater platelet inhibition at 1 month compared to clopidogrel 75 mg once daily in patients with stable coronary artery disease having percutaneous coronary intervention (Circulation 2018 Jun 21)

1 Oct 2018

triple antiplatelet therapy may reduce all-cause mortality and major adverse cardiovascular and cerebrovascular events without increased risk of major bleeding compared to standard dual antiplatelet therapy in patients with low responsiveness to clopidogrel having PCI (Circulation 2018 May 22)

7 Jan 2012

ACCF/AHA/SCAI 2011 guideline on percutaneous coronary intervention (Circulation 2011 Dec 6)

7 Jan 2012

ACCF/AHA/SCAI 2011 guideline on percutaneous coronary intervention (Circulation 2011 Dec 6)

CheckCircle

top